FDA Drug Tracker: Follow Every Approval Decision from Application to Market
An FDA drug tracker monitors the complete lifecycle of drug applications — from acceptance through advisory committee review to final approval or rejection decision. For biotech investors, a drug tracker is essential for timing catalyst-driven positions and managing event risk.
What an FDA Drug Tracker Monitors
A comprehensive FDA drug tracker follows four parallel data streams: (1) PDUFA review timelines — when applications were accepted and when decisions are due; (2) Advisory committee meetings — independent expert panels convened before major decisions; (3) FDA action letters — approval, Complete Response Letters (CRL), and accelerated approval decisions; (4) Post-market requirements — REMS programs, post-approval studies, and label negotiations. BiotechSign tracks all four streams with source citations from FDA announcements and SEC filings.
The FDA Drug Application Timeline
Understanding the FDA review timeline helps interpret tracker data. After submission, the FDA takes 60 days to accept or refuse to file an application. Once accepted, the PDUFA clock starts: 10 months for standard review, 6 months for priority review. At the 3-month mark before the PDUFA date, the FDA sometimes convenes an advisory committee. At month 10 or 6, the FDA issues its action letter — approval, CRL, or in rare cases a withdrawal request. BiotechSign's drug tracker visualizes this timeline for every tracked application.
Reading FDA Action Letters
When the FDA issues a decision, the action letter type determines the outcome. An approval letter confirms the drug can be marketed (though label terms may still be negotiated). A Complete Response Letter (CRL) means the FDA has identified deficiencies that must be resolved before approval — it's not a permanent rejection, but requires the company to respond with additional data, clinical trials, or manufacturing documentation. A withdrawal means the FDA has requested the applicant withdraw the application. BiotechSign tracks CRL details — the specific deficiencies cited — which helps assess re-submission timelines and probability.
Tracking Accelerated Approvals
The FDA's accelerated approval pathway allows drugs to be approved based on surrogate endpoints (biomarkers that reasonably predict clinical benefit) rather than definitive clinical outcomes. Accelerated approvals come with post-market study requirements. Tracking these is critical because the FDA has increasingly withdrawn accelerated approvals when post-market studies fail to confirm benefit. BiotechSign tracks accelerated approval status and required confirmatory trial deadlines.
Priority Review and Breakthrough Therapy Designations
The FDA grants expedited pathway designations that accelerate the review timeline and signal FDA receptivity to a drug. Priority Review (6-month vs 10-month PDUFA) is granted for drugs addressing serious conditions with potential for substantial improvement. Breakthrough Therapy Designation provides intensive guidance and organizational commitment from FDA senior staff. These designations are significant positive signals tracked by BiotechSign's drug tracker as filters in the screener.
Using the FDA Drug Tracker for Investment Research
For biotech investors, the most valuable use of an FDA drug tracker is identifying the 60-90 day window before major PDUFA decisions for established companies with strong signal profiles. Track: the application history (prior CRLs, extension history), the adcom vote if one occurred, the drug's competitive landscape, and any recent insider activity. BiotechSign's company pages integrate all this context in a single view, organized around the catalyst timeline.
BiotechSign tracks FDA catalysts, PDUFA dates, adcom meetings, and biotech signals for 8,000+ companies in real time.
Open BiotechSign →